Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 May;49(5):578-591.
doi: 10.1111/imj.14156.

Presenting signs and patient co-variables in Gaucher disease: outcome of the Gaucher Earlier Diagnosis Consensus (GED-C) Delphi initiative

Affiliations
Review

Presenting signs and patient co-variables in Gaucher disease: outcome of the Gaucher Earlier Diagnosis Consensus (GED-C) Delphi initiative

Atul Mehta et al. Intern Med J. 2019 May.

Erratum in

  • Corrigendum.
    [No authors listed] [No authors listed] Intern Med J. 2019 Aug;49(8):1059. doi: 10.1111/imj.14410. Intern Med J. 2019. PMID: 31387147 Free PMC article. No abstract available.

Abstract

Background: Gaucher disease (GD) presents with a range of signs and symptoms. Physicians can fail to recognise the early stages of GD owing to a lack of disease awareness, which can lead to significant diagnostic delays and sometimes irreversible but avoidable morbidities.

Aim: The Gaucher Earlier Diagnosis Consensus (GED-C) initiative aimed to identify signs and co-variables considered most indicative of early type 1 and type 3 GD, to help non-specialists identify 'at-risk' patients who may benefit from diagnostic testing.

Methods: An anonymous, three-round Delphi consensus process was deployed among a global panel of 22 specialists in GD (median experience 17.5 years, collectively managing almost 3000 patients). The rounds entailed data gathering, then importance ranking and establishment of consensus, using 5-point Likert scales and scoring thresholds defined a priori.

Results: For type 1 disease, seven major signs (splenomegaly, thrombocytopenia, bone-related manifestations, anaemia, hyperferritinaemia, hepatomegaly and gammopathy) and two major co-variables (family history of GD and Ashkenazi-Jewish ancestry) were identified. For type 3 disease, nine major signs (splenomegaly, oculomotor disturbances, thrombocytopenia, epilepsy, anaemia, hepatomegaly, bone pain, motor disturbances and kyphosis) and one major co-variable (family history of GD) were identified. Lack of disease awareness, overlooking mild early signs and failure to consider GD as a diagnostic differential were considered major barriers to early diagnosis.

Conclusion: The signs and co-variables identified in the GED-C initiative as potentially indicative of early GD will help to guide non-specialists and raise their index of suspicion in identifying patients potentially suitable for diagnostic testing for GD.

Keywords: algorithm; inborn error; lysosomal storage disease; metabolism; splenomegaly; thrombocytopenia.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Type 1 Gaucher disease case study.
Figure 2
Figure 2
The Gaucher Earlier Diagnosis Consensus initiative Delphi methodology.
Figure 3
Figure 3
Characteristics of the experts involved in the Gaucher Earlier Diagnosis Consensus initiative (n = 22). (A) Years of experience in managing patients with Gaucher disease; (B) number of patients the expert has treated; (C) clinical specialty.
Figure 4
Figure 4
Major signs in Gaucher disease with continuous variables. Panel members were asked to indicate the levels of anaemia, hepatomegaly, splenomegaly and thrombocytopenia that were considered consistent with, or unlikely to indicate, early type 1 Gaucher disease (GD) (n = 22) or early type 3 GD (n = 19), and the levels of hyperferritinaemia consistent with, or unlikely to indicate, type 1 GD. Value ranges were proposed by the chairs and categorised as mild, moderate or severe; panel members could also nominate a different range. (formula image), Consistent; (formula image), unlikely.

References

    1. Stirnemann J, Belmatoug N, Camou F, Serratrice C, Froissart R, Caillaud C et al. A review of Gaucher disease pathophysiology, clinical presentation and treatments. Int J Mol Sci 2017; 18: 441. - PMC - PubMed
    1. Pastores GM, Hughes DA. Gaucher disease In: Adam MP, Ardinger HH, Pagon RA, Wallace SE, LJH B, Stephens K, et al., eds. GeneReviews. Seattle, WA: University of Washington; 1993. - PubMed
    1. Mistry PK, Belmatoug N, vom Dahl S, Giugliani R. Understanding the natural history of Gaucher disease. Am J Hematol 2015; 90(Suppl 1): S6–11. - PubMed
    1. Mignot C, Gelot A, Bessieres B et al. Perinatal‐lethal Gaucher disease. Am J Med Genet A 2003; 120A: 338–44. - PubMed
    1. Azuri J, Elstein D, Lahad A, Abrahamov A, Hadas‐Halpern I, Zimran A. Asymptomatic Gaucher disease implications for large‐scale screening. Genet Test 1998; 2: 297–9. - PubMed